Please login to the form below

Not currently logged in
Email:
Password:

Kyprolis

This page shows the latest Kyprolis news and features for those working in and with pharma, biotech and healthcare.

Amgen set for Kyprolis label boost after CHMP backing

Amgen set for Kyprolis label boost after CHMP backing

boretezomib). The move was a bit dicey considering Kyprolis’ last head-to-head trial with the proteasome inhibitor in 2016 saw it fail to demonstrate superior progression-free survival. ... Reese added: “We’re proud to share these results with

Latest news

  • Amgen hopes its latest Kyprolis trial hits the mark with regulators Amgen hopes its latest Kyprolis trial hits the mark with regulators

    Sean Harper, executive vice president of research and development, Amgen, said: “Kyprolis has been demonstrated to be the most effective proteosome inhibitor available to patients with multiple myeloma. ... We are encouraged by the efficacy and safety

  • SMC gives green light for Amgen’s Kyprolis SMC gives green light for Amgen’s Kyprolis

    The committee also gives verdict on three other products. Multiple myeloma patients - who have received at least one prior therapy - in Scotland will soon be able to access Amgen’s Kyprolis

  • Amgen aspires to new Kyprolis label in the US and Europe Amgen aspires to new Kyprolis label in the US and Europe

    Newly-released analysis show Kyprolis exceeded its secondary endpoint of overall survival, reducing the risk of death by 21% over Rd alone. ... Patients in the trial received 18 cycles of Kyprolis with Rd administered twice-weekly at 27 mg.

  • FDA halts third Merck myeloma trial after patient deaths FDA halts third Merck myeloma trial after patient deaths

    All patients receiving Keytruda will stop treatment, according to Merck. KEYNOTE-023 is a phase I study looking at Keytruda in combination with standard care - Revlimid, dexamethasone or Amgen's Kyprolis

  • Amgen's Kyprolis tops Velcade in myeloma trial Amgen's Kyprolis tops Velcade in myeloma trial

    Amgen has insisted it remains committed to developing Kyprolis for front-line treatment of multiple myeloma despite the setback in the CLARION trial. ... It is currently designing a new phase III study that will pit Kyprolis against Velcade in

More from news
Approximately 16 fully matching, plus 20 partially matching documents found.

Latest Intelligence

  • Pharma deals in September 2015 Pharma deals in September 2015

    drug Kyprolis, acquired in the $10bn purchase of Onyx Pharmaceuticals.

  • Deal Watch table for August 2013 Deal Watch table for August 2013

    Onyx Pharmaceuticals / Amgen. Acquisition. Cancer drugs including Kyprolis, Nexavar and Stivarga.

  • Pharma deals during August 2013 Pharma deals during August 2013

    Indeed it is the fifth-largest biotechnology deal ever. The crown jewel Kyprolis (carfilzomib) is a proteasome inhibitor for the treatment of multiple myeloma which was launched in 2012 and has ... Then came the tussle over data from ongoing clinical

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....

Infographics